Catalent, Inc.

Symbol: CTLT

NYSE

55.98

USD

Market price today

  • -8.2564

    P/E Ratio

  • 7.3482

    PEG Ratio

  • 10.13B

    MRK Cap

  • 0.00%

    DIV Yield

Catalent, Inc. (CTLT) Stock Price & Analysis

Shares Outstanding

180.97M

Gross Profit Margin

0.19%

Operating Profit Margin

-0.21%

Net Profit Margin

-0.30%

Return on Assets

-0.12%

Return on Equity

-0.29%

Return on Capital Employed

-0.10%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Matti M. Masanovich
Full-time employees:17800
City:Somerset
Address:14 Schoolhouse Road
IPO:2014-07-31
CIK:0001596783

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

General Outlook

In simple terms, Catalent, Inc. has 180.974 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.187% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.213%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.300%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.124% return, is a testament to Catalent, Inc.'s adeptness in optimizing resource deployment. Catalent, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.292%. Furthermore, the proficiency of Catalent, Inc. in capital utilization is underscored by a remarkable -0.098% return on capital employed.

Stock Prices

Catalent, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $56.37, while its low point bottomed out at $55.75. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Catalent, Inc.'s stock market.

Liquidity Ratios

Analyzing CTLT liquidity ratios reveals its financial health of the firm. The current ratio of 248.07% gauges short-term asset coverage for liabilities. The quick ratio (153.96%) assesses immediate liquidity, while the cash ratio (22.10%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio248.07%
Quick Ratio153.96%
Cash Ratio22.10%

Profitability Ratios

CTLT profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -34.54% underscores its earnings before tax deductions. The effective tax rate stands at 13.10%, revealing its tax efficiency. The net income per EBT, 86.90%, and the EBT per EBIT, 162.10%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -21.31%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-34.54%
Effective Tax Rate13.10%
Net Income per EBT86.90%
EBT per EBIT162.10%
EBIT per Revenue-21.31%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.48, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding154
Days of Inventory Outstanding85
Operating Cycle205.87
Days of Payables Outstanding44
Cash Conversion Cycle161
Receivables Turnover3.01
Payables Turnover8.22
Inventory Turnover4.31
Fixed Asset Turnover1.09
Asset Turnover0.41

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.99, and free cash flow per share, -1.45, depict cash generation on a per-share basis. The cash per share value, 1.26, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.04, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.99
Free Cash Flow per Share-1.45
Cash per Share1.26
Operating Cash Flow Sales Ratio0.04
Free Cash Flow to Operating Cash Flow Ratio-1.45
Cash Flow Coverage Ratio0.04
Short Term Coverage Ratio3.29
Capital Expenditure Coverage Ratio0.41
Dividend Paid and Capex Coverage Ratio0.41

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 50.20%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.36, we discern the balance between debt and equity financing. The long-term debt to capitalization, 57.36%, and total debt to capitalization, 57.63%, ratios shed light on its capital structure. An interest coverage of -3.83 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio50.20%
Debt Equity Ratio1.36
Long Term Debt to Capitalization57.36%
Total Debt to Capitalization57.63%
Interest Coverage-3.83
Cash Flow to Debt Ratio0.04
Company Equity Multiplier2.71

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 23.62, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.28, reflects the portion of profit attributed to each share. The book value per share, 25.61, represents the net asset value distributed per share, while the tangible book value per share, 3.40, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share23.62
Net Income Per Share-1.28
Book Value Per Share25.61
Tangible Book Value Per Share3.40
Shareholders Equity Per Share25.61
Interest Debt Per Share27.81
Capex Per Share-3.22

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -11.43%, indicates top-line expansion, while the gross profit growth, -35.37%, reveals profitability trends. EBIT growth, -139.26%, and operating income growth, -139.26%, offer insights into operational profitability progression. The net income growth, -146.49%, showcases bottom-line expansion, and the EPS growth, -146.72%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-11.43%
Gross Profit Growth-35.37%
EBIT Growth-139.26%
Operating Income Growth-139.26%
Net Income Growth-146.49%
EPS Growth-146.72%
EPS Diluted Growth-147.23%
Weighted Average Shares Growth2.84%
Weighted Average Shares Diluted Growth1.69%
Dividends per Share Growth-100.00%
Operating Cash Flow Growth-40.55%
Free Cash Flow Growth-45.70%
10-Year Revenue Growth per Share53.95%
5-Year Revenue Growth per Share25.82%
3-Year Revenue Growth per Share14.36%
10-Year Operating CF Growth per Share22.86%
5-Year Operating CF Growth per Share-49.48%
3-Year Operating CF Growth per Share-50.94%
10-Year Net Income Growth per Share-222.01%
5-Year Net Income Growth per Share-301.16%
3-Year Net Income Growth per Share-186.88%
10-Year Shareholders Equity Growth per Share831.52%
5-Year Shareholders Equity Growth per Share209.17%
3-Year Shareholders Equity Growth per Share32.33%
3-Year Dividend per Share Growth per Share-100.00%
Receivables Growth-7.04%
Inventory Growth8.83%
Asset Growth2.62%
Book Value per Share Growth-6.01%
Debt Growth15.40%
R&D Expense Growth-21.74%
SGA Expenses Growth-1.54%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 12,417,160,000, captures the company's total value, considering both debt and equity. Income quality, -1.02, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 37.28%, indicates the value of non-physical assets, and capex to operating cash flow, -223.37%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value12,417,160,000
Income Quality-1.02
Research and Development to Revenue0.42%
Intangibles to Total Assets37.28%
Capex to Operating Cash Flow-223.37%
Capex to Revenue-13.63%
Capex to Depreciation-138.15%
Stock-Based Compensation to Revenue0.82%
Graham Number27.18
Return on Tangible Assets-3.43%
Graham Net Net-26.26
Working Capital1,172,000,000
Tangible Asset Value616,000,000
Net Current Asset Value-3,468,000,000
Invested Capital1
Average Receivables1,014,000,000
Average Payables424,000,000
Average Inventory733,000,000
Days Sales Outstanding83
Days Payables Outstanding48
Days of Inventory On Hand87
ROIC-1.06%
ROE-0.05%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.76, and the price to book ratio, 2.76, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.46, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -38.52, and price to operating cash flows, 56.29, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.76
Price to Book Ratio2.76
Price to Sales Ratio2.46
Price Cash Flow Ratio56.29
Price Earnings to Growth Ratio7.35
Enterprise Value Multiple-89.10
Price Fair Value2.76
Price to Operating Cash Flow Ratio56.29
Price to Free Cash Flows Ratio-38.52
Price to Tangible Book Ratio1.69
Enterprise Value to Sales2.90
Enterprise Value Over EBITDA157.18
EV to Operating Cash Flow47.58
Earnings Yield-2.96%
Free Cash Flow Yield-4.10%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Catalent, Inc. (CTLT) on the NYSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -8.256 in 2024.

What is the ticker symbol of Catalent, Inc. stock?

The ticker symbol of Catalent, Inc. stock is CTLT.

What is company IPO date?

IPO date of Catalent, Inc. is 2014-07-31.

What is company current share price?

Current share price is 55.980 USD.

What is stock market cap today?

The market cap of stock today is 10130924520.000.

What is PEG ratio in 2024?

The current 7.348 is 7.348 in 2024.

What is the number of employees in 2024?

In 2024 the company has 17800.